WO2002066953A3 - High throughput screen for specific inhibition of intramembranous proteolysis - Google Patents

High throughput screen for specific inhibition of intramembranous proteolysis Download PDF

Info

Publication number
WO2002066953A3
WO2002066953A3 PCT/US2002/004900 US0204900W WO02066953A3 WO 2002066953 A3 WO2002066953 A3 WO 2002066953A3 US 0204900 W US0204900 W US 0204900W WO 02066953 A3 WO02066953 A3 WO 02066953A3
Authority
WO
WIPO (PCT)
Prior art keywords
high throughput
specific inhibition
throughput screen
polypeptide
inhibition
Prior art date
Application number
PCT/US2002/004900
Other languages
French (fr)
Other versions
WO2002066953A2 (en
Inventor
Raphael Kopan
Original Assignee
Univ Washington
Raphael Kopan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Raphael Kopan filed Critical Univ Washington
Priority to AU2002252006A priority Critical patent/AU2002252006A1/en
Publication of WO2002066953A2 publication Critical patent/WO2002066953A2/en
Publication of WO2002066953A3 publication Critical patent/WO2002066953A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Abstract

The present invention relates to methods of screening treatments for the inhibition of proteolytic enzyme activity for cleavage of a transmembrane domain of a polypeptide of interest. Such methods may be utilized to screen for the inhibition of proteolytic enzyme activity for cleavage of one specific transmembrane domain of a polypeptide or of multiple transmembrane domains of a polypeptide for identification of an enzyme inhibitor that is specific for one substrate, yet does not act upon another substrate.
PCT/US2002/004900 2001-02-20 2002-02-20 High throughput screen for specific inhibition of intramembranous proteolysis WO2002066953A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002252006A AU2002252006A1 (en) 2001-02-20 2002-02-20 High throughput screen for specific inhibition of intramembranous proteolysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26995401P 2001-02-20 2001-02-20
US60/269,954 2001-02-20

Publications (2)

Publication Number Publication Date
WO2002066953A2 WO2002066953A2 (en) 2002-08-29
WO2002066953A3 true WO2002066953A3 (en) 2006-01-05

Family

ID=23029297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/004900 WO2002066953A2 (en) 2001-02-20 2002-02-20 High throughput screen for specific inhibition of intramembranous proteolysis

Country Status (2)

Country Link
AU (1) AU2002252006A1 (en)
WO (1) WO2002066953A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions

Also Published As

Publication number Publication date
AU2002252006A1 (en) 2002-09-04
AU2002252006A8 (en) 2006-11-02
WO2002066953A2 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
ATE203545T1 (en) SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES
WO2001066711A8 (en) Xylanase variants having altered sensitivity to xylanase inhibitors
EP2402438A3 (en) Protease screening methods and proteases identified thereby
HK1037605A1 (en) Sulfonamide inhibitors of aspartyl protease.
ATE279203T1 (en) USE OF SUBSTRATE SUBTRACTION LIBRARIES TO DIFFERENTIATE ENZYME SPECIFICITIES
WO2004020458A3 (en) Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
DE60121808D1 (en) USE OF A POLYPEPTIDE CONTAINING THE EXTRACELLULAR DOMAIN OF IL-20RA AND IL-20RB FOR THE TREATMENT OF INFLAMMATION
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
WO2000018899A3 (en) Angiotensin converting enzyme homolog and its use
MX9801093A (en) C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen.
IL170669A0 (en) Anaplastic lymphoma kinase assay, reagents and compositions thereof
NZ324921A (en) Cathepsin K crystal structure and methods of identifying inhibitors of this protease
DK1187933T3 (en) Betalactam-containing compounds
WO2002094985A3 (en) Beta-secretase substrates and uses thereof
WO2003076899A3 (en) Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
WO2003095475A3 (en) Peptide compounds and their use as protease substrates
WO2002012471A3 (en) Angiotensin converting enzyme homolog and uses therefor
WO2002066953A3 (en) High throughput screen for specific inhibition of intramembranous proteolysis
WO2002072786A3 (en) Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
PT941975E (en) CEMENT FOR INJECTION CONTAINING CORROSION INHIBITORS
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
WO1997027220A3 (en) Substrates and inhibitors for cysteine protease ich-1
WO2002008280A3 (en) SCREENING METHODS BASED ON SUPERACTIVATED αVβ3 INTEGRIN
WO2005056043A3 (en) Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
WO1999032627A3 (en) The protein tyrosine kinase substrate lat and its use in the identification of (ant)agonists of the kinase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP